Hypertension and dyslipidemia combined therapeutic approaches
Treating blood pressure (BP) alone may provide only limited benefits while it is
recommendable to manage the total cardiovascular risk. To date, several studies have …
recommendable to manage the total cardiovascular risk. To date, several studies have …
Angiotensin II, hypercholesterolemia, and vascular smooth muscle cells: a perfect trio for vascular pathology
A St. Paul, CB Corbett, R Okune, MV Autieri - International Journal of …, 2020 - mdpi.com
Cardiovascular disease is the leading cause of morbidity and mortality in the Western and
developing world, and the incidence of cardiovascular disease is increasing with the longer …
developing world, and the incidence of cardiovascular disease is increasing with the longer …
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
I Lingvay, N Beetz, R Sennewald… - Postgraduate …, 2020 - Taylor & Francis
Objectives Fixed-dose combination (FDC) therapy can improve outcomes in type 2 diabetes
(T2D). We evaluated the bioequivalence of 2 doses of an FDC of extended-release …
(T2D). We evaluated the bioequivalence of 2 doses of an FDC of extended-release …
Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine
MA Alam, YA Bin Jardan, B Alzenaidy… - Journal of Pharmacy …, 2021 - academic.oup.com
Objectives To study the effect of Zingiber officinale and Hibiscus sabdariffa on
pharmacokinetics and pharmacodynamics of amlodipine. Methods Hypertension was …
pharmacokinetics and pharmacodynamics of amlodipine. Methods Hypertension was …
[PDF][PDF] 丹参酮ⅡA 联合阿托伐他汀对大鼠动脉粥样硬化的治疗作用研究
叶泽森, 周里岩, 黄光业, 薛照芸, 刘培庆… - 生命科学 …, 2022 - smkx.hunnu.edu.cn
阿托伐他汀和丹参酮ⅡA 在临床上已用于治疗动脉粥样硬化. 然而, 两者联用治疗动脉粥样硬化
的协同作用仍不明确. 为了考察丹参酮ⅡA 联合阿托伐他汀能否增强阿托伐他汀对动脉粥样硬化 …
的协同作用仍不明确. 为了考察丹参酮ⅡA 联合阿托伐他汀能否增强阿托伐他汀对动脉粥样硬化 …
Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats
MA Alam, YA Bin Jardan, M Raish… - Current Drug …, 2020 - ingentaconnect.com
Background: The present article is related to in-vitro and in-vivo herb-drug interaction
studies. Objectives: This study aimed to investigate the effect of Nigella sativa and fenugreek …
studies. Objectives: This study aimed to investigate the effect of Nigella sativa and fenugreek …
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart …
AFG Cicero, F Fogacci, E Rizzoli, M Giovannini… - Nutrition, Metabolism …, 2022 - Elsevier
Background and aims To evaluate the long-term effect of simultaneous treatment of
hypertension and hypercholesterolemia with angiotensin-converting enzyme (ACE) …
hypertension and hypercholesterolemia with angiotensin-converting enzyme (ACE) …
Herb–drug interaction: pharmacokinetics and pharmacodynamics of anti-hypertensive drug amlodipine besylate in presence of Lepidium sativum and Curcuma longa
MA Alam, YA Bin Jardan, M Raish, AM Al-Mohizea… - Xenobiotica, 2022 - Taylor & Francis
Abstract Effects of Lepidium sativum and Curcuma longa were investigated on
pharmacokinetics and pharmacodynamics of antihypertensive drug (amlodipine) …
pharmacokinetics and pharmacodynamics of antihypertensive drug (amlodipine) …
[HTML][HTML] Медикаментозная терапия артериальной гипертонии и дислипидемии: возможности препарата Липертанс (на примере клинического наблюдения)
ВВ Кашталап - Российский кардиологический журнал, 2022 - cyberleninka.ru
В статье, проиллюстрированной клиническим наблюдением, представлены
эпидемиологические данные о высокой распространенности коморбидности …
эпидемиологические данные о высокой распространенности коморбидности …
[HTML][HTML] Возможности применения комбинированной терапии у пациентов c сочетанием артериальной гипертензии и дислипидемии
ТВ Горохова, НБ Перепеч - Российский кардиологический …, 2022 - cyberleninka.ru
В настоящей статье представлен обзор имеющихся данных о роли артериальной
гипертензии и дислипидемии как ведущих факторов, определяющих характер …
гипертензии и дислипидемии как ведущих факторов, определяющих характер …